A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema)

未提供0 个研究点目标入组 165 人开始时间: 待定

适应症

试验速览

暂无简介。

•Participants must meet the following criteria:
•1.Are 18 to 64 years of age
•2.Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs
•3.Have moderate to severe AD as defined by the following at screening and baseline visits:
•Affected body surface area (BSA) greater than or equal to 10% and up to 60%;
•Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;
•Eczema Area and Severity Index (EASI) greater than or equal to 16;
•Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit
•4.Do not have a suitable prescribed medicine for AD.
•5.Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs)

•Participants must not meet the following criteria:
•1.Have an infection that requires treatment
•2.Have other skin conditions other than AD
•3.Have severe uncontrolled asthma
•4.Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit

发起方

未提供